Related Experiment Video
Updated: Apr 19, 2026
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Novel membrane-based targets - Therapeutic potential in gynecological cancers
M Gizzi1, P Pautier2, C Lhomme2
1Department of Medicine, Gustave Roussy, University of ParisSud, Villejuif, France; Medical Oncology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Abstract:
Recent advances have been made in the molecular profiling of gynecological tumors. These discoveries have led to the development of targeted therapies that have the potential to disrupt molecular pathways involved in the oncogenesis or tumor progression. In this review, we highlight areas of recent progress in the field of membrane receptor inhibitors in gynecological malignancies and describe the biological rationale underlying the inhibition of these receptors. We will introduce drug immuno-conjugates, and give an update on the biological rationale and the clinical studies involving agents directed against EGFR, HER3, IGFR, MET, FGFR, NOTCH, and TRAIL. We also discuss the challenge facing these new therapies.
Insights
Targeted therapies are emerging for gynecological cancers by inhibiting membrane receptors like EGFR and HER3. This review covers their biological basis and clinical studies, offering hope for improved cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gynecological tumors are increasingly understood through molecular profiling.
- Targeted therapies aim to disrupt oncogenesis and tumor progression pathways.
- Membrane receptors are key targets in gynecological cancer treatment.
Purpose of the Study:
- To review recent progress in membrane receptor inhibitors for gynecological malignancies.
- To describe the biological rationale for inhibiting specific membrane receptors.
- To update on clinical studies of targeted agents and discuss challenges.
Main Methods:
- Literature review of recent advances in molecular profiling and targeted therapies.
- Analysis of biological rationale for inhibiting key membrane receptors.
- Summary of clinical studies involving EGFR, HER3, IGFR, MET, FGFR, NOTCH, and TRAIL inhibitors.
Main Results:
- Significant progress has been made in developing targeted therapies for gynecological cancers.
- Inhibitors targeting EGFR, HER3, IGFR, MET, FGFR, NOTCH, and TRAIL show therapeutic potential.
- Drug immuno-conjugates represent a novel therapeutic approach.
Conclusions:
- Targeted inhibition of membrane receptors offers a promising strategy for gynecological cancer treatment.
- Further research and clinical studies are needed to overcome challenges and optimize these therapies.
- Understanding the molecular pathways is crucial for developing effective targeted treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:38Mitogens and the Cell Cycle
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers